Amgen Highlights Q1 Growth, AI Gains and Obesity Drug MariTide Plans
AMGN•Amgen highlighted first-quarter growth and AI-driven operational gains while detailing preparations for potential 2026 launches of its late-stage pipeline, including obesity candidate MariTide. The company also scheduled a June 9 presentation at the Goldman Sachs 47th Annual Global Healthcare Conference featuring CFO Peter Griffith and EVP Murdo Gordon.
1. Jefferies Investor Conference Highlights
At a Jefferies investor event, Amgen executives underscored first-quarter sales growth and advances in AI-driven drug discovery processes. They highlighted a robust late-stage pipeline with potential 2026 launches, notably the obesity candidate MariTide, and outlined strategic initiatives to sustain long-term expansion.
2. Goldman Sachs Conference Presentation
Amgen confirmed it will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, featuring CFO Peter Griffith and EVP Murdo Gordon. The webcast will be available live and archived on the company website for investors and the public for at least 90 days.
